Latest Reimbursement News

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

Bridge SaaS Limited reported a robust September quarter, buoyed by its majority-owned Brightside subsidiary's profitability and participant growth, while preparing to launch new NDIS services in New South Wales.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

Resolution Minerals Ltd is set to acquire a processing mill and tungsten stockpiles adjacent to its Horse Heaven Project in Idaho, aiming to accelerate U.S. production of critical metals antimony and tungsten.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.

4DMedical Limited has secured FDA clearance and immediate Medicare reimbursement for its groundbreaking CT – VQ™ lung imaging technology, accelerating commercial adoption across the US, Brazil, and Australia.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Novonix Limited has achieved its first mass production of industrial-grade synthetic graphite and secured significant funding, advancing its position in North America's battery materials supply chain.

ImpediMed Limited reported a record A$3.6 million quarterly revenue and expanded its US hospital footprint with over 600 SOZO units installed. The launch of SOZO Pro targets new heart failure markets, while reimbursement coverage accelerates across US states.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.